AbbVie and Genmab Report Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Relapsed/Refractory DLBCL
New drug combo helps lymphoma patients live longer without worsening disease, cutting risk by ~60%—without chemotherapy.
/ 4 items
#GMAB↓
Genmab's Epcoritamab Trial Falls Short on Key Survival Metric
Genmab's Phase 3 trial for epcoritamab shows mixed results in lymphoma patients, missing its overall survival goal despite some improvements.
Genmab Stops Development of Acasunlimab to Focus on Key Cancer Treatments
Genmab discontinues acasunlimab development to prioritize high-impact cancer therapies including EPKINLY, petosemtamab, and Rina-S in its late-stage pipeline.
Genmab's $8 Billion Move: Acquiring Merus to Lead the Next Wave of Cancer Antibody Therapeutics
Denmark's Genmab is acquiring Dutch drugmaker Merus for $8 billion to secure petosemtamab, a late-stage, breakthrough treatment for head and neck cancer, bolstering Genmab's proprietary oncology pipeline and accelerating its evolution into a global biotechnology leader.